Delivery Order SPE2DB20D2104-SPE2DB23FR42T
- Not listed
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The award, a Delivery Order valued at $1,442.63, is for the supply of Naftifine HCL 1% Cream, a pharmaceutical product. The contract has a firm fixed price pricing type and an ultimate completion date of April 11, 2024. Amerisourcebergen Drug Corp, through its Corporate...
- This federal contract award to Amerisourcebergen Drug Corporation's Corporate Office Division is a Delivery Order valued at $1,385.12 for the supply of 4565752999 - Naftifine HCL 2% Cream 45GM. The contract was awarded by the Defense Logistics Agency (DLA) and does not have a set-aside designation. Amerisourcebergen is a major pharmaceutical distributor that holds several Indefinite Delivery Contracts (IDCs) with the DLA and other agencies, valued at up to $999,999,999 and $750,000 respectively,...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a Delivery Order (DO) valued at $1,139.56 under the Defense Logistics Agency (DLA) Troop Support Medical Indefinite Delivery Contract (IDC). The award covers the delivery of NAFTIFINE HCL 1% CREAM 60GM, a pharmaceutical product, to support federal healthcare programs. This DO does not have a set-aside designation, indicating open competition. Amerisourcebergen, a major pharmaceutical distributor, has...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corporation's Corporate Office Division. The $1,181.05 firm fixed price delivery order is for the supply of NAFTIFINE HCL 1% CR 1S, a pharmaceutical product. The award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for the provision of a comprehensive...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is a Delivery Order valued at $1,873.54 for the supply of 4556611118 - Naftifine HCL 1% Cream 60GM. The contract has an ultimate completion date of March 21, 2022 and was awarded on March 18, 2022 under a Firm Fixed Price pricing type. This award is not designated as a set-aside contract. Amerisourcebergen Drug Corp holds a...
- This federal contract award, with a ceiling value of $1,073.97, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the delivery of naftifine HCL 2% gel (60 gm). The contract is a firm fixed price delivery order with a performance period through March 11, 2024. Amerisourcebergen Drug Corp is a prime contractor that has received numerous federal contract awards from DLA Troop Support Medical to supply pharmaceuticals,...
- This federal contract award, valued at $4,273.51, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Naftifine HCL 2% Cream, a topical antifungal medication, with a period of performance through December 2023. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The award, valued at $8,908.42, is a firm fixed price delivery order for the supply of NAFTIN 1% GEL 40GM, a pharmaceutical product. This delivery order is part of a larger indefinite delivery contract (IDC) awarded to Amerisourcebergen Drug Corp by DLA, with a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,961.53 to AmerisourceBergen Drug Corp for Naftifine HCL 1% Cream in 60-gram units. This firm fixed-price contract, awarded on August 4, 2025, with an ultimate completion date of August 5, 2025, represents a non-competitive set-aside delivery order under DLA's pharmaceutical supply chain. The product will be performed and delivered from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The delivery order, valued at $1,395.45, is for the supply of NAFTIFINE HCL 1% CR 1S, a topical antifungal medication. This contract has no set-aside designation and is expected to be completed by August 2, 2024. Amerisourcebergen is a significant supplier of pharmaceutical products and medical supplies to the U.S. federal...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB23FR42TDelivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, a Delivery Order valued at $1,158.90, is for the supply of Naftifine HCL 1% Cream in 60 gram units. The award has no set-aside designation, indicating an open competition. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which is registered in the System for Award Management (SAM.gov) through January 2026. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. Amerisourcebergen Drug Corp also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, covering similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 12/13/22 |